Veru Inc.

VERU

US92536C1036

Personal Products

Real-time Estimate Cboe BZX Other stock markets 12:53:20 2024-04-26 pm EDT			5-day change	1st Jan Change
1.235 ^USD	+2.07%		-5.34%	+72.22%

Apr. 15	Oppenheimer Cuts Veru Price Target to $5 From $7, Maintains Outperform Rating	MT
Apr. 01	Veru Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	CI

Veru Inc. Reports Earnings Results for the Full Year Ended September 30, 2021

December 02, 2021 at 12:22 pm EST

Veru Inc. reported earnings results for the full year ended September 30, 2021. For the full year, the company reported sales was USD 61.26 million compared to USD 42.59 million a year ago. Net income was USD 7.39 million compared to net loss of USD 18.97 million a year ago. Basic earnings per share from continuing operations was USD 0.1 compared to basic loss per share from continuing operations of USD 0.28 a year ago. Diluted earnings per share from continuing operations was USD 0.09 compared to diluted loss per share from continuing operations of USD 0.28 a year ago.

Latest news about Veru Inc.

Oppenheimer Cuts Veru Price Target to $5 From $7, Maintains Outperform Rating	Apr. 15	MT
Veru Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Apr. 01	CI
Raymond James Starts Very With Outperform Rating, $3 Price Target	Mar. 28	MT
Certain Options of Veru Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	Mar. 12	CI
Certain Common Stock of Veru Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	Mar. 12	CI
Veru Inc. Appoints Louis Aronne as Chief Medical Advisor and A Member of the Scientific Advisory Board	Mar. 12	CI
Veru Inc. Announces New Scientific Advisory Board for Its Enobosarm Program for High Quality Weight Loss	Feb. 20	CI
Transcript : Veru Inc., Q1 2024 Earnings Call, Feb 08, 2024	Feb. 08
Veru Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application for its Phase 2b Clinical Study	Feb. 06	CI
Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with Glp-1 Drugs for Weight Loss	Jan. 08	CI
Transcript : Veru Inc. - Special Call	Jan. 04
Veru Prices $33 Million Offering; Shares Fall	Dec. 14	MT
Veru Launching Public Offering of Shares	Dec. 13	MT
Veru Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Dec. 08	CI
North American Morning Briefing : Stock Futures, -2-	Dec. 04	DJ
Veru Inc. Reports Muscle Data from 5 Clinical Studies of Enobosarm	23-10-04	CI
Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication	23-09-26	CI
Veru Inc. Announces Clinical Data from Its Discontinued Phase 3 ARTEST Clinical Trial of Enobosarm Monotherapy	23-09-11	CI
Oppenheimer Adjusts Veru Price Target to $7 From $9, Maintains Outperform Rating	23-08-14	MT
Transcript : Veru Inc., Q3 2023 Earnings Call, Aug 10, 2023	23-08-10
Earnings Flash (VERU) VERU Posts Q3 Revenue $3.3M	23-08-10	MT
Veru Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-10	CI
Veru Inc.(NasdaqCM:VERU) dropped from Russell 2500 Index	23-06-23	CI
Veru Inc.(NasdaqCM:VERU) dropped from Russell Small Cap Completeness Index	23-06-23	CI
Veru Inc.(NasdaqCM:VERU) dropped from Russell Small Cap Comp Growth Index	23-06-23	CI

Chart Veru Inc.

Duration

Period

More charts

Company Profile

Veru Inc. is a biopharmaceutical company. The Company is focused on developing medicines for the for the treatment of hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and other viral-related ARDS and for the management of breast and prostate cancers. The Company offers two FDA approved products within its sexual health program, including ENTADFI (tadalafil 5mg and finasteride 5mg capsule), for the treatment of benign prostatic hyperplasia and FC2 Female Condom (internal condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.

Sector

Personal Products

Calendar

2024-05-08 - Q2 2024 Earnings Release (Projected)

More about the company